Case Studies

J. B. (renal transplant-acute care)
B. W. (liver transplant-acute care)
J. P. (liver transplant-subacute and chronic care)
M. S. (renal transplant-subacute and chronic care)
D. D. (renal transplant-chronic care)
Close This Window

TRANSPLANT CERTIFICATE PROGRAM MODULE 6

IMPLEMENTING PATIENT CARE MANAGEMENT: ACUTE and CHRONIC CARE of the KIDNEY or LIVER TRANSPLANT RECIPIENT

Robert E. Dupuis, David Taber, Amy Fann


Selected References

General Reviews

1. Mitchison HC, Newberger, JM. Medical complications of liver transplantation. Digestive Diseases 1993;11:78-101.

2. Silkensen JR. Long-term complication in renal transplantation. Journal of the American Society of Nephrology 2000;11:582-588.

3. Venkateswara KR. Posttransplant medical complications. Surg Clin North Amer 1998;78(1):113-132.

Infections

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. The New England Journal of Medicine 1998;338(24):1741-1751.

2. Singh N. Infectious diseases in the liver transplant recipient. Seminars in Gastrointestinal Disease 1998;9(3):136-146.

3. Dummer S, Kusne S. Liver transplantation and related infections. Seminars in Respiratory Infections 1993;8(3):191-198.

4. Hibberd PL and Rubin RH. Renal transplantation and related infections. Seminars in Respiratory infections 1993;8(3):216-224.

5. Branten AJ, Beckers PJ Tiggeler RG, Hoitsma AJ. Pneumocystis carinii pneumonia in renal transplant recipients. Nephrology, Dialysis, and Transplantation 1995;10:1194-1197.

6. Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation. Transplantation 1998;65(5):641-647.

Long-Term Immunosuppressive Strategies

1. Helderman JH, Van Buren DH, Amend WJ, Pirsch JD. Chronic immunosuppression of the renal transplant patient. Journal of the American Society of Nephrology 1994;4(Suppl 1):S2-S9.

2. Matthew TH. Optimal long-term immunotherapy protocols. Transplantation Proceedings 1999;31:1102-1103.

3. McMaster P, Gunson B, Min X, Afonso R, and Bastos J. Liver transplantation: changing goals in immunosuppression. Transplantation Proceedings 1998;30:1819-1821.

4. Riordan SM, Williams R. Tolerance after liver transplantation: does it exist and can immunosuppression be withdrawn? Journal of Hepatology 1999;31:1106-1119.

Osteoporosis

1. Epstein S, Shane E, Bilezikian JP. Organ transplantation and osteoporosis. Current Opinion in Rheumatology 1995;7:255-261.

2. Coen G. Fracturing osteoporosis after kidney transplantation – what are the options? Nephrology, Dialysis, and Transplantation 1996;11:567-569.

3. McCaughan GW, Feller RB. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Digestive Diseases 1994;12:223-231.

4. Anonymous. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis and Rheumatism 1996;39(11):1791-1801.

Post-Transplant Diabetes Mellitus

1. Jindal RM, Sidner RA, Milgram ML. Post-transplant diabetes mellitus: the role of immunosuppression. Drug Safety 1997;16(4):242-257.

2. Jindal RM. Post-transplant diabetes mellitus – a review. Transplantation 1994;12:1289-1298.

3. Navasa M, Bustamante J, Marroni C, Gonzalez E, Hernan A, et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. Journal of Hepatology 1996;25:64-71.

Malignancy

1. Savage P, Waxman J. Post-transplant lymphoproliferative disease. Q J Med 1997;90:497-503.

2. Penn I. Tumors after renal and cardiac transplantation. Hematology/Oncology Clinics of North America 1993;7(2):431-445.

3. Sheil AG. Patterns of malignancies following renal transplantation. Transplantation Proceedings 1999;31:1263-1265.

4. Tan-Shalaby J, Tempero M. Malignancies after liver transplantation: a comparative review. Seminars in Liver Disease 1995;15(2):156-164.

Acute/Chronic Rejection

1. Suthanthiran M, Strom TB. Mechanisms and management of acute allograft rejection. Surg Clin North Amer 1998;78:77-94.

2. Ponticelli C. Progression of renal damage in chronic rejection. Kidney International 2000;57(Suppl 75):S62-S70.

3. Jindal RM, Hariharan S. Chronic rejection in kidney transplants: an in-depth review. Nephron 1999;83:13-24.

4. Hayry P, Aavik E, Savolainen H. Mechanisms of chronic rejection. Transplantation Proceedings 1999;31(Suppl 7A):5S-8S.

5. Tiney NL, Kusaka M, Pratschke J, Wilhelm M. Chronic rejection. Transplantation Proceedings 1998;30:1590-1594.

6. Knechtle SJ. Rejection of the liver transplant. Seminars in Gastrointestinal Disease 1998;9(3):126-135.

Recurrence of Disease

1. Matthew TH. Recurrence of disease following renal transplantation. American Journal of Kidney Diseases 1988;12(2):85-96.

2. Reich D, Rothstein K, Manzarbeitia C, Munoz S. Common medical diseases after liver transplantation. Seminars in Gastrointestinal Disease 1998;9(3):110-125.

3. McGory RW, Ishtani MB, Oliveira WM, Stevenson WC, McCullough CS, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61(9):1358-1364.

4. Lumbreras C, Colina F, Loinaz MJ, Domingo AF, Domingez P, et al. Clinical, virological, and histological evolution of hepatitis C infection in liver transplant recipients. Clinical Infectious Diseases 1998;26:48-55.

Immunizations

1. Grabenstein JD, Baker JR. Immunization and organ transplantation. Hosp Pharm 1999;339-351.

2. Harmon WE. Immunization practices in transplant recipients. Lierature Scan Transplant 2000;16:4-5.

OTC’s, Medication Non-Adherence, and Drug-Drug and Drug-Herb Interactions

1. Smolinske SC. Dietary Supplement-drug interactions. JAMWA 1999;54(4):191-192.

2. Trotter JF. Drugs that interact with immunosuppressant agents. Seminars in Gastrointestinal Disease 1998;9(3):147-153.

3. Lake KD, Canafax DM. Important interactions of drugs with immunosuppressive agents used in transplant recipients. Journal of Antimicrobial Chemotherapy 1995;36(Suppl B)11-22.

4. Fugh-Berman A. Herb-drug interactions. The Lancet 2000;355:134-138.

5. Miller LG. Herbal medicinals: selected clinical consideration focusing on known or potential drug-herb interactions. Archives of Internal Medicine 1998;158:2200-2211.

6. Ellingson T, Wipke-Tevis D, Livesay T. The use of over-the-counter medication by transplant recipients: a guideline. Journal of Transplant Coordination 1999;9:17-24.

7. Newton SE. Promoting adherence to transplant medication regimens: a review of behavioral analysis. Journal of Transplant Coordination 1999;9:13-16.

Development of a Patient Care Plan and Reimbursement for Provision of Pharmaceutical Services

1. McCallian DJ, Carlstedt BC, Rupp MT. Elements of a pharmaceutical care plan. Journal of the American Pharmaceutical Association 1999;39(1):82-83.

2. Canaday BR, Yarborough PC. Documenting pharmaceutical care: creating a standard. The Annals of Pharmacotherapy 1994;28:1292-1296.

3. Poirier S, Buffington DE, Memoli GA. Billing third party payers for pharmaceutical care services. Journal of the American Pharmaceutical Association 1999;39(1):50-64.

4. Rupp MT. Standardizing documentation for filing pharmaceutical care claims. American Pharmacy 1995;NS35(9):26-30.